文献速递肿瘤 PET/CT

超越αvβ3整合素:用于PET显像αvβ6、αvβ8、αvβ3和α5β1整合素亚型的多聚配体

There is a world beyond αvβ3-integrin: Multimeric ligands for imaging of the integrin subtypes αvβ6, αvβ8, αvβ3, and α5β1 by positron emission tomography.
PubMed 文献 · EJNMMI Res · 2021-10-12

本文综述了德国研究基金会CRC 824项目框架下,利用TRAP螯合剂构建对称三聚体肽类和非肽类整合素配体,并开发系列68Ga标记PET显像剂的研究。临床前数据表明这些示踪剂对α5β1、αvβ8、αvβ6和αvβ3整合素具有高潜力,其中αvβ6靶向PET在胰腺癌患者中不出现脱靶摄取,显著改善显像效果。

要点

  • TRAP螯合剂可构建对称三聚体整合素配体,68Ga标记后用于PET显像。
  • 临床前数据支持α5β1、αvβ8、αvβ6和αvβ3整合素靶向PET显像潜力。
  • αvβ6靶向PET在胰腺癌患者中无脱靶摄取,优于αvβ3靶向PET。

核心结论

  • 靶向多种整合素(尤其是αvβ6)的新型放射性药物已显示临床潜力,将在未来诊疗一体化中发挥越来越重要的作用。

研究设计与样本

  • 本文为综述,描述了德国研究基金会多组跨学科资助项目CRC 824框架下整合素相关PET显像剂的研究工作。

主要发现

  • 利用gallium-68螯合剂TRAP构建了多种肽类和非肽类整合素配体的对称三聚体,临床前数据提示所得Ga-68示踪剂对α5β1、αvβ8、αvβ6和αvβ3整合素PET显像具有高潜力。
  • 针对前三种整合素(α5β1、αvβ8、αvβ6),作者提供了人类癌症中的额外免疫组化数据,提示未来多种临床应用。
  • 在胰腺癌患者中应用αvβ3和αvβ6整合素示踪剂显示,与αvβ3靶向PET不同,αvβ6整合素PET不具有脱靶摄取特征,从而能显著改善该类癌症的显像。

临床怎么用

  • αvβ6整合素靶向PET在胰腺癌患者中不出现脱靶摄取,可显著改善显像,提示其临床转化潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the context of nuclear medicine and theranostics, integrin-related research and development was, for most of the time, focused predominantly on 'RGD peptides' and the subtype αvβ3-integrin. However, there are no less than 24 known integrins, and peptides without the RGD sequence as well as non-peptidic ligands play an equally important role as selective integrin ligands. On the other hand, multimerization is a well-established method to increase the avidity of binding structures, but multimeric radiopharmaceuticals have not made their way into clinics yet. In this review, we describe how these aspects have been interwoven in the framework of the German Research Foundation's multi-group interdisciplinary funding scheme CRC 824, yielding a series of potent PET imaging agents for selective imaging of various integrin subtypes. RESULTS: The gallium-68 chelator TRAP was utilized to elaborate symmetrical trimers of various peptidic and non-peptidic integrin ligands. Preclinical data suggested a high potential of the resulting Ga-68-tracers for PET-imaging of the integrins α5β1, αvβ8, αvβ6, and αvβ3. For the first three, we provide some additional immunohistochemistry data in human cancers, which suggest several future clinical applications. Finally, application of αvβ3- and αvβ6-integrin tracers in pancreatic carcinoma patients revealed that unlike αvβ3-targeted PET, αvβ6-integrin PET is not characterized by off-target uptake and thus, enables a substantially improved imaging of this type of cancer. CONCLUSIONS: Novel radiopharmaceuticals targeting a number of different integrins, above all, αvβ6, have proven their clinical potential and will play an increasingly important role in future theranostics.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Steiger K, Quigley NG, Groll T, et al. There is a world beyond αvβ3-integrin: Multimeric ligands for imaging of the integrin subtypes αvβ6, αvβ8, αvβ3, and α5β1 by positron emission tomography. EJNMMI Res. 2021. PMID: 34636990. doi:10.1186/s13550-021-00842-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。